MerkusPJFM, van Essen-ZandliletEEM, ParievlietE, BorsboomG, SterkPJ, KerrebijnKF, . Changes of nebulizer output over the years. Eur Respir J1992;5:488–491.
4.
SterkPJ, PlompA, van de VateJF, QuanjerPH. Physical properties of aerosols produced by several jet and ultrasonic nebulisers. Bull Eur Physiopathol Respir1984;20:65–72.
5.
AlvineGF, RodgersP, FitzsimmonsKM, AhrensRC. Disposable jet nebulizers: how reliable are they?Chest1991;101:316–319.
6.
AllenSC, PriorA.What determines whether an elderly patient can use a metered dose inhaler correctly?Br J Dis Chest1986;80:45–49.
7.
LindgrenS, BakeB, LarssonS.Clinical consequences of inadequate inhalation technique in asthma therapy. Eur J Respir Dis1987;70:93–98.
8.
OrehekJ, GayrardP, GrimaudC, CharpinJ.Patient error in use of bronchodilator metered aerosols. Br Med J1976;1:76.
9.
GuidryGG, BrownWD, StognerSW, GeorgeRB. Incorrect use of metered dose inhalers by medical personnel. Chest1992;101:31–33.
NewmanSP, ClarkeSW. The proper use of metered dose inhalers. Chest1984;86:342–344.
12.
DeBlaquiereP, ChristensenDB, CarterWB, MartinTK. Use and misuse of metered-dose inhalers by patients with chronic lung disease. Am Rev Respir Dis1989;140:910–916.
13.
SpeizerFE, DollR, HeafP.Observations on recent increase in mortality from asthma. Br Med J1968;1:339–343.
SpeizerFE, WegmanDH, RamirezA.Palpitation rates associated with fluorocarbon exposure in a hospital setting. N Engl J Med1975;292:624–626.
16.
BrooksSM, MintzS, WeissE.Changes occurring after Freon inhalation. Am Rev Respir Dis1972;105:640–643.
17.
DolleryCT, WilliamsFM, DraffanGH, WiseG, SahyounH, PatersonJW, . Artificial blood levels of fluorocarbons in asthmatic patients following use of pressurized aerosols. Clin Pharmacol Ther1974;15:59–66.
18.
PatersonJW, SudlowMF, WalkerSR. Blood levels of fluorinated hydrocarbons in asthmatic patients after inhalation of pressurised aerosols. Lancet1971;2:565.
19.
SilvergladeA.Cardiac toxicity of aerosol propellants (editorial). JAMA1972;222:827–828.
20.
NewmanSP. Metered dose pressurized aerosols and the ozone layer. Eur Respir J1990;3:395–397.
21.
BalmesJR. Propellant gases in metered dose inhalers: their impact on the global environment. Respir Care1991;36:1037–1044.
22.
KernDG, FranklinH.Asthma in respiratory therapists. Ann Intern Med1989;110:767–773.
23.
DavisDS. Pharmacokinetics of inhaled substances. Postgrad Med J1975;51(Suppl 7):69–75.
24.
NewhouseMT, DolovichMB. Current concepts—control of asthma by aerosols. N Engl J Med1986;315:870–874.
25.
RuffinRE, KenworthyMC, NewhouseMT. Response of asthmatic patients to fenoterol inhalation: a method of quantifying the airway bronchodilator dose. Clin Pharmacol Ther1978;23:338–345.
26.
FullerHD, DolovichMB, PosmituckG, Wong PackW, NewhouseMT. Pressurized aerosol versus jet aerosol delivery to mechanically ventilated patients: comparison of dose to the lungs. Am Rev Respir Dis1990;141:440–444.
27.
FernandezA, LazaroA, GarciaE, AragonC, CerdaE.Bronchodilators in patients with chronic obstructive pulmonary disease on mechanical ventilation: utilization of metered-dose inhalers. Am Rev Respir Dis1990;141:164–168.
28.
CromptonGK. Problems patients have using pressurized aerosol inhalers. Eur J Respir Dis1982;63(Suppl 119):101–104.
29.
O'ConnellMB, HewittJM, LackerTE. Consistency of evaluators assessing inhaler technique. Ann Allergy1991;67:603–608.
30.
DeTullioPL, CorsonME. Effect of pharmacist counseling on ambulatory patients: use of aerosolized bronchodilators. Am J Hosp Pharm1987;44:1802–1806.
31.
SelfTH, BrooksJB, LiebermanP, RyanMR. The value of demonstration and role of the pharmacist in teaching the correct use of pressurized bronchodilators. Can Med Assoc J1983;128:129–131.
32.
WoodcockA.Training aid for pressurized inhalers. Br J Dis Chest1980;74:395–397.
33.
NewmanSP. Aerosol generators and delivery systems. Respir Care1991;36:939–951.
34.
GayPC, PatelHG, NelsonSB, GillesB, HubmayrRD. Metered dose inhalers for bronchodilator delivery in intubated, mechanically ventilated patients. Chest1991;99:66–71.
35.
CameronD, ClayM, SilvermanM.Evaluation of nebulizers for use in neonatal ventilatory circuits. Crit Care Med1990;18:886–870.
36.
MacIntyreNR, SilverRM, MillerCW, SchuylerF, ColemanRE. Aerosol delivery in intubated, mechanically ventilated patients. Crit Care Med1985;13:81–85.
37.
AhrensRC, RiesRA, PopendorfW, WieseJA. The delivery of therapeutic aerosols through endotracheal tubes. Pediatr Pulmonol1986;2:19–26.
38.
CroganSJ, BishopMJ. Delivery efficiency of metered dose aerosols given via endotracheal tubes. Anesthesiology1989;68:964–966.
39.
YuCP, NicolaidesP, SoongTT. Effect of random airway sizes on aerosol deposition. Am Ind Hyg Assoc J1979;40:999–1005.
40.
KimCS, LewarsGA, SacknerMA. Measurement of total lung aerosol deposition as an index of lung abnormality. J Appl Physiol1988;64:1527–1536.
41.
DolovichMB, SanchisJ, RossmanC, NewhouseMT. Aerosol penetrance: a sensitive index of peripheral airway obstruction. J Appl Physiol1976;40:468–471.
42.
IlowiteJS, GorvoyJD, SmaldoneGC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am Rev Respir Dis1987;136:1445–1449.
43.
LindgrenS, BakeB, LarssonS.Clinical consequences of inadequate inhalation technique in asthma therapy. Eur J Respir Dis1987;70:93–98.
44.
PedersenS.Treatment of acute bronchoconstriction in children with a tube spacer aerosol and a dry powder inhaler. Allergy1985;40:300–303.
45.
AssoufiBK, HodsonME. High dose salbutamol in chronic airflow obstruction: comparison of nebulizer with Rotacaps. Respir Med1989;83:415–420.
46.
van LunterenE, CorenoA.Inhaled albuterol powder for pulmonary function testing. Chest1992;101:985–988.
47.
ReinarzJA, PierceAk, MaysBM, SanfordJP. The potential role of inhalation therapy equipment in nosocomial pulmonary infection. J Clin Invest1965;44:831–839.
48.
PierceAK, SanfordJP, ThomasGD, LeonardJS. Long term evaluation of decontamination of inhalation therapy equipment and the occurrence of necrotizing pneumonia. N Engl J Med1970;282:528–531.
49.
PierceAK, SanfordJP. Bacterial contamination of aerosols. Arch Intern Med1973;131:156–159.
50.
WexlerMR, RhameFR, BlumenthalMN, CameronSB, JuniBA, FishLA. Transmission of gram-negative bacilli to asthmatic children via home nebulizers. Ann Allergy1991;66:267–271.
51.
MestitzH, CoplandJ, McDonaldC.Comparison of outpatient nebulized vs metered dose inhaler terbutaline in chronic airflow obstruction. Chest1989;96:1237–1240.
52.
JenkinsSE, HeatonRW, FultonTJ, MoxhamJ.Comparison of domiciliary nebulized salblutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. Chest1987;91:804–807.
O'ReillyJF, GouldG, KendrickAH, LaszloG.Domiciliary comparison of terbutaline treatment by metered dose inhaler with and without conical spacer in severe and moderately severe chronic asthma. Thorax1986;41:766–770.
55.
MorganMDL, SinghBV, FrameMH, WIlliamsSJ. Terbutaline aerosol given through pear spacer in acute severe asthma. Br Med J1982;285:849–850.
56.
CissikJH, BodeFR, SmithJA. Double-blind crossover study of five bronchodilator medications and two delivery methods in stable asthma. Chest1986;90:489–493.
LevinsonH, ReillyA, WorslelyGII. Spacing devices and metered dose inhalers in childhood asthma. J Pediatr1985;107:662–668.
59.
TurnerTR, CorkeryKJ, EclemanD, GelbAM, LipavskyA, SheppardD.Equivalence of inhaler with reservoir bag for treatment of acute airflow obstruction. Chest1988;93:476–481.
60.
BerryR, ShintoR, WongF, DespersJ, LightR.Nebulizer vs spacer for bronchodilator delivery in patients hospitalized for acute exacerbations of COPD. Chest1989;96:1241–1246.
61.
BowtonDL, GoldsmithWM, HaponikEF. Substitution of metered-dose inhalers for hand-held nebulizers: success and cost savings in a large acute-care hospital. Chest1992;101:305–308.
62.
TenholderMF, BrysonMJ, WhitlockWL. A model for conversion from small volume nebulizer to metered dose inhaler aerosol therapy. Chest1992;101:634–637.
63.
JasperAC, MohsenifarZ, KahanS, GoldbergHS, KoernerSK. Cost-benefit comparison of aerosol bronchodilator methods in hospitalized patients. Chest1987;91:614–618.
64.
SummerW, ElstonR, TharpeL, NelsonS, HaponikEF. Aerosol bronchodilatordelivery methods: relative impact on pulmonary function and cost of respiratory care. Arch Intern Med1989;149:618–623.
65.
GonzalezER, BurkeTG. Review of the status of intermittent positive pressure breathing therapy. Drug Intell Clin Pharm1984;18:974–976.
66.
AHCPR. Intermittent positive pressure breathing (IPPB) therapy. AHCPR Health Technology Assessment Reports1991;1. Washington DC: U.S. Department of Health and Human Services, 1991.
67.
O'DonohueWJJr. IPPB past and present (point of view). Respir Care1982;27:588–590.
68.
Centers for Disease Control. Update: Universal Precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus, and other blood-borne pathogens in health care settings. MMWR1988;37:377–388.
69.
ArnowPM, ChouT, WeilD, ShapiroEN, KretzschmarC.Nosocomial Legionnaires' disease caused by aerosolized tap water from respiratory devices. J Infect Dis1982;146:460–467.
70.
Faculty and Working Group. American Association for Respiratory Care. Aerosol Consensus Conference Statement—1991. Respir Care1991;36:916–921.
71.
NewmanSP. Delivery of therapeutic aerosols. In: WitekTJ, SchachterEN, eds. Advances in respiratory care pharmacology. Philadelphia: JB Lippincott, 1988:53–82.
72.
MorenF, NewhouseMT, DolovichMD, eds. Aerosols in medicine: principles, diagnosis, and therapy. Amsterdam: Elsevier Science Publishers, 1985.
73.
WitekTJ, SchachterEN. Delivery of drugs by aerosol. In: Respiratory care pharmacology and therapeutics. Philadelphia: WB Saunders, 1993.
74.
KimC, EldridgeM, SacknerM.Oropharyngeal deposition and delivery aspects of metered-dose inhaler aerosols. Am Rev Respir Dis1987;135:157–164.
BlakeKV, HoppeM, HarmanE, HendelesL.Relative amount of albuterol delivered to lung receptors from a metered-dose inhaler and nebulizer solution: bioassay by histamine bronchoprovocation. Chest1991;101:309–315.
77.
NewhouseM, DolovichM.Aerosol therapy: nebulizer vs metered dose inhaler. Chest1987;91:799–800.
78.
MorleyTF, MarozsanE, ZappasodiSJ, GordonR, GriesbackRm, GiudiceJC. Comparison of beta-adrenergic agents delivered by nebulizer vs metered dose inhaler with InspirEase in hospitalized asthmatic patients. Chest1988;94:1205–1210.
79.
NewhouseMT. Principles of aerosol therapy. Chest1982; (Suppl):39S–41S.
80.
NewhouseMT, DolovichM.Aerosol therapy of reversible obstruction: concepts and clinical applications. Chest1987;91 (Suppl):58S–64S.
OlivensteinR, WolkoveN, CohenC, FrankH, KreismanH.A comparison of responses to albuterol delivered by two aerosol devices. Chest1986;90:392–395.
83.
GervaisA, BeginP.Bronchodilatation with a metered-dose inhaler plus an extension, using tidal breathing vs jet nebulization. Chest1987;92:822–824.
84.
ClausenJL. Self-administration of bronchodilators: cost effective? (editorial). Chest1987;91:475.
85.
ShimC, WilliamsMH. The adequacy of inhalation of aerosol from canister nebulizers. Am J Med1980;69:891–894.
86.
PatersonIC, CromptonGK. Use of pressurized aerosols by asthmatic patients. Br Med J1976;1:76–77.
87.
EpsteinSW, ManningCPR, AshleyMJ, CoreyPN. Survey of the clinical use of pressurized aerosol inhalers. Can Med Assoc J1972;120:813–816.
88.
WilliamsTJ. The importance of aerosol technique: does speed of inhalation matter?Br J Dis Chest1982;76:223–228.
89.
PedersenS, HansenOR, FuglsangG.Influence of inspiratory flow rate upon the effect of a Turbuhaler. Arch Dis Child1990;65:308–319.
90.
EngelT, HeinigJM, MedsenF, NikanderK.Peak inspiratory flowrate and inspiratory vital capacity of patients with asthma measured with or without a new dry powder inhaler device (Turbuhaler). Eur Respir J1990;3:1037–1041.
91.
NewmanSP. Aerosol inhalers. Br Med J1990;300:1286–1287.
SchuhS, ParkinP, RajanA, CannyG, HealyR, RiederM, . High- versus low-dose, frequently administered, nebulized albuterol in children with severe, acute asthma. Pediatrics1989;83:513–518.
94.
NelsonHS, RaineDJr, DonerHC, PoseyWC. Subsensitivity to the bronchodilator action of albuterol produced by chronic administration. Am Rev Respir Dis1977;116:871–878.
95.
PlummerAL. The development of drug tolerance to beta2 adrenergic agents. Chest1978;73(Suppl):949–957.